# BioRun

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biorun

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.biorun.com
- Latest round: Series A (Jan 5, 2024)
- Investors on record: 4

## About

Established in 2011 and based in Wuhan, China, BioRun operates as a biotechnology company dedicated to providing services such as gene cloning and protein expression vector construction. It has sub-branch offices in Sanya and Huanggang. The company acquired PCT US patent authorization and has applied for more than ten patents. The founder and CEO of the company, Yang Li graduated from Wuhan University. In 2022, the company obtained the title of High-tech Enterprise. In January 2024, BioRun closed series A funding.

The company mainly provides platforms for the research and application of functional genes in animals and plants. The platforms include genetic transformation platform, detection platform, protein platform, and synthetic biology platform. The company's platforms can provide services such as gene cloning, gene synthesis, DNA cloning and construction, and crop transgenic research. BioRun also provides an e-commercial platform named BioRun Strict Selection, which provides products such as molecular biology agents, culture media, and biological reagents. The service targets include scientific research institutes and seed companies.

The company will build multi-omics platform.

## Funding rounds

- Series A, Jan 5, 2024 — Addor Capital, Zhongli Capital, Baiying Bio-industry Investment, Wuhan High-tech Industry Investment Private Fund Management

## Investors

- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- Zhongli Capital — Series A
- Baiying Bio-industry Investment (https://capitalatlas.ai/funds/baiying-bio-industry-investment) — Series A
- Wuhan High-tech Industry Investment Private Fund Management (https://capitalatlas.ai/funds/wuhan-high-tech-industry-investment-private-fund-management) — Series A